Dexchlorpheniramine Uses, Dosage, and Side Effects

Introduction

Dexchlorpheniramine is an antihistamine medication used to treat various allergic conditions, including hay fever, common cold symptoms, and urticaria. Dexchlorpheniramine belongs to the class of drugs known as antihistamines, which work by blocking the effects of histamine, a natural chemical released in the body during an allergic reaction [1]. By suppressing histamine, dexchlorpheniramine helps alleviate symptoms such as itching, watery eyes, sneezing, and runny nose.

Pharmacological Classification

Dexchlorpheniramine is classified as an antihistamine, specifically an H1-receptor antagonist. It is an enantiomer of chlorpheniramine, meaning it has the same chemical formula but a different spatial arrangement of atoms [2]. In addition to its antihistaminic properties, dexchlorpheniramine also exhibits anticholinergic effects, which contribute to its drying and sedative side effects.

Mechanism of Action

Dexchlorpheniramine works by competitively binding to histamine H1 receptors, preventing histamine from attaching to these receptors and triggering allergic reactions. By blocking the action of histamine, dexchlorpheniramine helps reduce inflammation, swelling, and other symptoms associated with allergies [3]. The anticholinergic properties of dexchlorpheniramine also contribute to its therapeutic effects by reducing secretions and providing temporary relief from respiratory conditions.

Uses and Indications

Dexchlorpheniramine is indicated for the symptomatic treatment of various allergic conditions, including:

• Allergic rhinitis (hay fever)
• Common cold symptoms
• Urticaria (hives)
• Allergic skin reactions (e.g., sunburns, insect bites)
• Other allergic conditions characterized by itching, sneezing, and runny nose

Dexchlorpheniramine helps provide temporary relief from these symptoms, making it easier for patients to breathe and function normally.

Dosage Forms and Administration

Dexchlorpheniramine is available in various dosage forms, including:

• Oral tablets (2 mg and 4 mg)
• Oral solution (2 mg/5 mL)
• Combination products with other medications, such as pseudoephedrine

The recommended dosage of dexchlorpheniramine varies depending on the age of the patient and the severity of the condition. For adults and children 12 years and older, the typical dose is 2 mg every 4-6 hours, not to exceed 12 mg in 24 hours. For children 6-11 years old, the recommended dose is 1 mg every 4-6 hours, not to exceed 6 mg in 24 hours. Dexchlorpheniramine should be used at the lowest effective dose for the shortest duration necessary to relieve symptoms.

Side Effects and Adverse Reactions

Like all medications, dexchlorpheniramine may cause side effects. The most common side effects include:

• Drowsiness and sedation
• Dry mouth, nose, and throat
• Dizziness and headache
• Nausea and vomiting
• Blurred vision
• Constipation

Less common but more severe side effects may include difficulty breathing, severe drowsiness, and allergic reactions. Long-term use of dexchlorpheniramine may lead to dependence and tolerance, requiring higher doses to achieve the same therapeutic effects.

Interactions

Dexchlorpheniramine may interact with other medications, including:

• Other antihistamines and anticholinergics
• CNS depressants, such as alcohol, sedatives, and tranquilizers
• MAO inhibitors
• Tricyclic antidepressants

These interactions may increase the risk of side effects or reduce the effectiveness of the medications. Patients should inform their healthcare provider about all medications they are taking before starting dexchlorpheniramine.

Warnings and Precautions

Dexchlorpheniramine should be used with caution in certain populations, including:

• Pregnant women: Dexchlorpheniramine may cause harm to the fetus and should only be used if the benefits outweigh the risks.
• Nursing mothers: Dexchlorpheniramine may pass into breast milk and cause side effects in the nursing infant.
• Children: Dexchlorpheniramine may cause paradoxical excitation in children and should be used with caution.
• Elderly patients: Older adults may be more sensitive to the effects of dexchlorpheniramine and may experience increased side effects.

Dexchlorpheniramine may also impair mental alertness and motor skills, making it unsafe to drive or operate heavy machinery while taking the medication.

Overdose and Management

Symptoms of dexchlorpheniramine overdose may include severe drowsiness, confusion, hallucinations, seizures, and coma. In case of overdose, patients should seek immediate medical attention. Treatment may involve supportive care, such as monitoring vital signs and administering activated charcoal to reduce absorption of the medication.

Brands and Availability

Dexchlorpheniramine is available under various brand names, including Polaramine and Polmon. It is also available as a generic medication. The availability of dexchlorpheniramine may vary by country and prescription status.

FAQs

Is dexchlorpheniramine safe for long-term use?

Dexchlorpheniramine is generally safe for short-term use but may cause dependence and tolerance with long-term use. Patients should follow the recommended dosage and duration of treatment to minimize the risk of side effects.

Can dexchlorpheniramine be used to treat allergic reactions to food?

Dexchlorpheniramine may help alleviate symptoms of mild allergic reactions to food but should not be used as a substitute for epinephrine in case of severe allergic reactions (anaphylaxis).

References and Further Reading

1. Church, M. K., & Maurer, M. (2012). H1-antihistamines and urticaria: how can we predict the best drug for our patient?. Clinical & Experimental Allergy, 42(10), 1423-1429.
2. Agrawal, D. K. (2001). Pharmacology and clinical efficacy of desloratadine as an anti-allergic and anti-inflammatory drug. Expert Opinion on Investigational Drugs, 10(3), 547-560.
3. Richardson, G. S., Roehrs, T. A., Rosenthal, L., Koshorek, G., & Roth, T. (2002). Tolerance to daytime sedative effects of H1 antihistamines. Journal of Clinical Psychopharmacology, 22(5), 511-515.